NCT04115631 2026-03-02
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03615664 2025-01-16
BURGUND
Polish Lymphoma Research Group
Phase 2 Completed
NCT01216683 2023-06-29
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01412879 2021-10-29
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01045681 2020-12-07
BVD
Intergroupe Francophone du Myelome
Phase 2 Completed
NCT00939328 2015-03-06
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
SWOG Cancer Research Network
Phase 2 Withdrawn